Double Dose 4-AP on Functional Recovery After Spinal Cord Injury

Summary

The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used twice-daily in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.

Timeline

Start

2025-02-01

Primary completion

2026-03-01

Completion

2026-12-30

Drugs

Indications